CloudQuartzabout 2 hours ago
Abivax shares drop amid cancer risks in IBD trial
1 min read
Abivax stock price fell sharply following reports of serious adverse events during its inflammatory bowel disease clinical study. The biotechnology company faces scrutiny after participants developed unexpected cancers while receiving the experimental therapy for gastrointestinal conditions.
Level
Hype check
Tap to vote and see what everyone thinks.
